Streetbeat News

Products Services

HARP

MRK

Merck & Co Inc (NYSE:MRK) reported a surprise Q4 2023 profit with sales of $14.63 billion, up 6% Y/Y, driven by oncology, vaccines, and hospital acute care. Keytruda sales rose 21% to $6.61 billion, while Lagevrio sales dropped 77%. Adjusted EPS was $0.03, beating consensus. The company forecasts 2024 sales of $62.7 billion-$64.2 billion and adjusted EPS of $8.44-$8.59. Merck also announced the acquisition of Harpoon Therapeutics Inc (NASDAQ:HARP), expected to close in H1 2024.

Portfolio Pulse from Vandana Singh

February 01, 2024 | 3:43 pm

RCL

During a conference call, a Royal Caribbean executive mentioned that the company has less inventory available to book for 2024 compared to the same period a year ago.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 3:09 pm

NRBO

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) shares surged after the FDA cleared its IND application for DA-1726, a novel obesity treatment. The company plans to start a Phase 1 clinical trial in the first half of 2024. DA-1726, a dual oxyntomodulin analog agonist, showed superior weight loss in mouse models compared to existing treatments. NeuroBo's stock soared 41% on heavy trading volume, significantly above its 100-day average.

Portfolio Pulse from Erica Kollmann

February 01, 2024 | 3:08 pm

NRBO

NeuroBo Pharmaceuticals' shares surged following the FDA's clearance of the IND for a Phase 1 clinical trial of DA-1726, aimed at treating obesity.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 3:06 pm

SILO

Silo Pharma has announced its pipeline prioritization for 2024, focusing on mental health, chronic pain, and neurology. This strategic move aims to address significant unmet medical needs in these areas.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 3:02 pm

ANRO

Alto Neuroscience, Inc (ANRO) is set to IPO on February 2nd on the NYSE, offering shares between $14.00 and $16.00 with a 180-day insider lock-up period ending July 31, 2024. The company focuses on developing personalized psychiatric treatments through neurobiology research.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 3:00 pm

GUTS

Fractyl Health, Inc (NASDAQ:GUTS) is set to begin trading on NASDAQ under the ticker GUTS on February 2, with an IPO price range of $14.00 to $16.00 per share. The company, specializing in metabolic therapeutics for diseases like type 2 diabetes and obesity, has a 180-day insider lock-up period ending on July 31, 2024.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 3:00 pm

LLY

Market whales have shown a predominantly bearish stance on Eli Lilly (NYSE:LLY) through recent options trades, with a sentiment split of 11% bullish and 88% bearish. A total of 9 significant options trades were identified, with a notable focus on strike prices ranging from $590 to $700. The current market status of LLY shows a slight increase in stock price to $646.97, with an upcoming earnings report in 5 days. Analyst opinions vary, with an average price target of $670, but with differing views from Barclays, Cantor Fitzgerald, and Wells Fargo.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 2:47 pm

RACE

Ferrari N.V. (NYSE:RACE) reported a strong fourth-quarter performance with sales growth of 11% year-on-year to $1.639 billion, surpassing analyst estimates. The company saw an 11% increase in cars and spare parts revenue and a 7% increase in engine sales, although total shipments fell by 2% to 3,245 units. Adjusted EBITDA and net profit rose significantly, with EPS beating consensus estimates. Ferrari's 2023 shipments increased by 3.3%, driven by the Purosangue and higher deliveries of the 296 and SF90 families. The company forecasts a positive outlook for 2024 with an adjusted EPS of at least €7.50 and net revenues over €6.4 billion. Shares surged by 10.29% to $381.50.

Portfolio Pulse from Nabaparna Bhattacharya

February 01, 2024 | 2:45 pm

AVT

Avnet has announced the release of the latest version of its RFSoC Explorer Toolbox, Version 3.0, which enables full mmWave antenna to bits prototyping. This release marks a significant advancement in Avnet's offerings, providing developers with enhanced capabilities for creating and testing new mmWave applications.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 2:41 pm